Health AI Central
Share:
Peer-Reviewed Publication
Therapie2026;81(2):132-139.January 1, 2026Journal Article

Artificial intelligence in personalized prescription: A narrative review of promise, peril, and practicality.

Guillaume L Martin1, Louis Létinier2
1Synapse Medicine, 33000 Bordeaux, France.
2Synapse Medicine, 33000 Bordeaux, France. Electronic address: louis@synapse-medicine.com.
PubMed DOI

Abstract

The integration of artificial intelligence (AI), particularly large language models (LLMs), into clinical prescription practices represents a transformative shift in healthcare, promising to offer enhanced therapeutic precision, reduced errors, and personalized care. However, rapid adoption is outpacing validation and governance. This narrative review critically examines the benefits, risks, and i…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.